KR20240117650A - Rna 암 백신 - Google Patents

Rna 암 백신 Download PDF

Info

Publication number
KR20240117650A
KR20240117650A KR1020247024776A KR20247024776A KR20240117650A KR 20240117650 A KR20240117650 A KR 20240117650A KR 1020247024776 A KR1020247024776 A KR 1020247024776A KR 20247024776 A KR20247024776 A KR 20247024776A KR 20240117650 A KR20240117650 A KR 20240117650A
Authority
KR
South Korea
Prior art keywords
mrna
cancer
epitope
epitopes
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247024776A
Other languages
English (en)
Korean (ko)
Inventor
니콜라스 밸리언트
테드 애쉬번
크리스틴 홉슨
Original Assignee
모더나티엑스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모더나티엑스, 인크. filed Critical 모더나티엑스, 인크.
Publication of KR20240117650A publication Critical patent/KR20240117650A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020247024776A 2017-02-01 2017-10-26 Rna 암 백신 Ceased KR20240117650A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762453465P 2017-02-01 2017-02-01
US201762453444P 2017-02-01 2017-02-01
US62/453,444 2017-02-01
US62/453,465 2017-02-01
US201762558238P 2017-09-13 2017-09-13
US62/558,238 2017-09-13
KR1020197025539A KR20190120233A (ko) 2017-02-01 2017-10-26 Rna 암 백신
PCT/US2017/058595 WO2018144082A1 (en) 2017-02-01 2017-10-26 Rna cancer vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025539A Division KR20190120233A (ko) 2017-02-01 2017-10-26 Rna 암 백신

Publications (1)

Publication Number Publication Date
KR20240117650A true KR20240117650A (ko) 2024-08-01

Family

ID=63040027

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197025539A Ceased KR20190120233A (ko) 2017-02-01 2017-10-26 Rna 암 백신
KR1020247024776A Ceased KR20240117650A (ko) 2017-02-01 2017-10-26 Rna 암 백신

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197025539A Ceased KR20190120233A (ko) 2017-02-01 2017-10-26 Rna 암 백신

Country Status (11)

Country Link
US (2) US20190351040A1 (enExample)
EP (1) EP3576751A4 (enExample)
JP (2) JP7731656B2 (enExample)
KR (2) KR20190120233A (enExample)
CN (1) CN110505877A (enExample)
AU (1) AU2017397458B2 (enExample)
CA (1) CA3052255A1 (enExample)
MA (1) MA47401A (enExample)
RU (2) RU2022106357A (enExample)
SG (2) SG11201906895WA (enExample)
WO (1) WO2018144082A1 (enExample)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EA201891001A1 (ru) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
EP3364982A4 (en) 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
MX390014B (es) 2016-03-18 2025-03-20 Immune Sensor Llc Compuestos de dinucleótidos cíclicos y métodos de uso.
WO2017182634A1 (en) * 2016-04-22 2017-10-26 Curevac Ag Rna encoding a tumor antigen
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
AU2017268394A1 (en) 2016-05-18 2019-01-03 Modernatx, Inc. Polynucleotides encoding relaxin
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
CA3052803A1 (en) * 2017-02-07 2018-08-16 Nantcell, Inc. Maximizing t-cell memory and compositions and methods therefor
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
EP4397757A3 (en) 2017-08-18 2024-10-23 ModernaTX, Inc. Rna polymerase variants
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
KR20210038886A (ko) * 2018-06-27 2021-04-08 모더나티엑스, 인크. 개인화된 암 백신 에피토프 선택
IL280110B2 (en) 2018-07-26 2025-07-01 Curevac Netherlands B V Cancer vaccines ready for use
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
JP7640452B2 (ja) 2018-09-19 2025-03-05 モデルナティエックス インコーポレイテッド 高純度ｐｅｇ脂質及びそれらの使用
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
JP7712207B2 (ja) 2018-10-19 2025-07-23 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法
MA54192A (fr) * 2018-11-07 2021-09-15 Modernatx Inc Vaccins à arn contre le cancer
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
JP2022518399A (ja) * 2019-01-14 2022-03-15 ジェネンテック， インコーポレイテッド Ｐｄ－１軸結合アンタゴニスト及びｒｎａワクチンを用いてがんを処置する方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
EP3937973A1 (en) * 2019-03-11 2022-01-19 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
WO2020198338A1 (en) * 2019-03-25 2020-10-01 Ohio State Innovation Foundation Combination immunoregulation and uses thereof
WO2020242720A1 (en) * 2019-05-02 2020-12-03 University Of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
MA56060A (fr) * 2019-05-31 2022-04-06 Modernatx Inc Dosage de lymphocytes t ayant subi une expansion
AU2020289484A1 (en) * 2019-06-07 2021-12-23 Emory University KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
CN110172480B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
WO2021038089A1 (en) * 2019-08-29 2021-03-04 Universität Zürich Minimal messenger rnas and uses thereof
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
US20230002799A1 (en) * 2019-12-11 2023-01-05 Vanderbilt University Methods of synthesizing mrna and functional proteins from synthetic double stranded dna
CA3168945A1 (en) * 2020-01-30 2021-08-05 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
WO2021155149A1 (en) * 2020-01-31 2021-08-05 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
JP2023512707A (ja) * 2020-02-05 2023-03-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ｒｎａ負荷ナノ粒子およびがんの治療のためのそれらの使用
NZ793241A (en) 2020-03-11 2025-10-31 Advansix Resins & Chemicals Llc Surfactants for oil and gas production
US20210290765A1 (en) * 2020-03-11 2021-09-23 Advansix Resins & Chemicals Llc Surfactants for healthcare products
JP2023522193A (ja) * 2020-04-17 2023-05-29 ザ フランシス クリック インスティチュート リミティッド 抗原プール
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
US11130787B2 (en) * 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
US12385039B2 (en) 2020-07-02 2025-08-12 Life Technologies Corporation Trinucleotide cap analogs, preparation and uses thereof
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4194006A4 (en) * 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
AU2021324883A1 (en) 2020-08-12 2023-03-23 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CA3198727A1 (en) 2020-10-20 2022-04-28 St Pharm Co., Ltd. Oligonucleotide for 5'-capped rna synthesis
US20230391871A1 (en) * 2020-10-22 2023-12-07 The Regents Of The University Of California Monoamine oxidase blockade therapy for treating cancer through regulating tumor associated macrophages (tams)
WO2022120560A1 (zh) * 2020-12-08 2022-06-16 深圳市瑞吉生物科技有限公司 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用
US20240299516A1 (en) * 2020-12-21 2024-09-12 University Of Florida Research Foundaton, Inc. Multilamellar rna nanoparticle vaccine against cancer
CN114717229B (zh) * 2021-01-05 2024-09-10 麦塞拿治疗(香港)有限公司 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4313072A1 (en) * 2021-03-26 2024-02-07 ModernaTX, Inc. Pertussis vaccine
NL2028681B1 (en) * 2021-04-02 2022-10-17 Nutcracker Therapeutics Inc Materials and methods for generating antigen-specific t cells and treating diseases
CN113186285B (zh) * 2021-05-10 2022-05-24 深圳市展行生物有限公司 一种辅助诊断胃癌的方法及其使用的miRNA组合
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN113577258B (zh) * 2021-07-31 2024-04-16 山东兴瑞生物科技有限公司 一种双靶点mRNA疫苗及其制备方法
CN115703714B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
IL311304A (en) 2021-09-13 2024-05-01 Oncodna A method for creating personal neoantigens from a patient's growth
EP4147713A1 (en) * 2021-09-13 2023-03-15 OncoDNA A rna vaccine comprising an rna pool generated from a double-stranded dna pool
EP4147712A1 (en) 2021-09-13 2023-03-15 OncoDNA Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient
EP4429682A2 (en) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN116376942A (zh) * 2021-12-31 2023-07-04 广州国家实验室 mRNA疫苗
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN119866224A (zh) * 2022-07-28 2025-04-22 加拿大干细胞技术公司 编码连接抗原的多核苷酸以及其用途
CN115992152A (zh) * 2022-09-22 2023-04-21 浙江大学医学院附属第一医院 一种用于乙型肝炎病毒治疗性mRNA疫苗及其制备方法与应用
EP4600361A1 (en) * 2022-10-07 2025-08-13 University of Tsukuba Design method and production method for nucleic acid construct and protein complex
IL320317A (en) * 2022-10-19 2025-06-01 Kalivir Immunotherapeutics Inc Nucleic acids encoding soluble pd-1 and il-12 and uses thereof
CN120225259A (zh) * 2022-10-31 2025-06-27 磨石生物公司 组合组无细胞dna监测
WO2024097874A1 (en) * 2022-11-03 2024-05-10 Modernatx, Inc. Chemical stability of mrna
EP4364752A1 (en) 2022-11-07 2024-05-08 OncoDNA Improved vaccine
CN116970614A (zh) * 2022-12-29 2023-10-31 达冕疫苗(广州)有限公司 编码ny-eso-1的核糖核酸疫苗的组合物和方法
EP4651888A1 (en) * 2023-01-17 2025-11-26 The University Of Hong Kong Cancer immunotherapy by delivery of mrna
CN116585342B (zh) * 2023-05-23 2024-08-16 源生生物科技(青岛)有限责任公司 包含miRNA的活性成分及其应用
WO2025054383A1 (en) * 2023-09-06 2025-03-13 Modernatx, Inc. Chemical stability of mrna
WO2025080869A1 (en) * 2023-10-11 2025-04-17 The Regents Of The University Of California Pancreatic cancer immunotherapy using cationic lipid and polymer nanocarriers for co-delivery of kras neoantigens and sting and/or other immunomodulators to boost the cancer immunity cycle and treat liver metastasis
WO2025117816A1 (en) * 2023-12-01 2025-06-05 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025153053A1 (en) * 2024-01-17 2025-07-24 Abogen Biosciences (Shanghai) Co., Ltd. Composition and methods for inducing antigen specific immunity against kras mutant cells
WO2025158069A1 (en) * 2024-01-25 2025-07-31 Rheinische Friedrich-Wilhelms-Universität Bonn CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒
CN117883558B (zh) * 2024-03-15 2024-06-14 山东兴瑞生物科技有限公司 靶向肝肿瘤个性化mRNA疫苗的制备方法
CN119874872B (zh) * 2025-01-17 2025-11-25 武汉大学 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
PT3023788T (pt) * 2010-05-14 2020-05-18 Massachusetts Gen Hospital Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
HRP20230443T1 (hr) * 2011-05-24 2023-09-15 BioNTech SE Individualizirana cjepiva protiv raka
NO2746404T3 (enExample) * 2011-08-16 2018-05-05
US20140255472A1 (en) * 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
AU2013243952A1 (en) * 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2014233424B2 (en) * 2013-03-15 2017-03-16 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
EP3053592B1 (en) * 2013-10-01 2025-04-23 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
WO2016011226A1 (en) * 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
JP6912384B2 (ja) * 2015-04-22 2021-08-04 キュアバック アーゲー 癌疾患の処置のための、ｒｎａ含有組成物
EP3307305A4 (en) * 2015-06-10 2019-05-22 Modernatx, Inc. TARGETED ADAPTIVE VACCINES
WO2017020026A1 (en) * 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US20180318409A1 (en) * 2015-10-22 2018-11-08 Modernatx, Inc. Cancer vaccines
CN110402145A (zh) * 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法

Also Published As

Publication number Publication date
JP7731656B2 (ja) 2025-09-01
US20250134978A1 (en) 2025-05-01
RU2019127381A (ru) 2021-03-02
CN110505877A (zh) 2019-11-26
US20190351040A1 (en) 2019-11-21
RU2022106357A (ru) 2022-03-24
WO2018144082A1 (en) 2018-08-09
SG10202108307YA (en) 2021-08-30
RU2019127381A3 (enExample) 2021-06-17
AU2017397458A1 (en) 2019-08-15
KR20190120233A (ko) 2019-10-23
JP2023164537A (ja) 2023-11-10
EP3576751A1 (en) 2019-12-11
AU2017397458B2 (en) 2025-07-10
EP3576751A4 (en) 2021-08-04
NZ755780A (en) 2023-10-27
JP2020506189A (ja) 2020-02-27
RU2768829C2 (ru) 2022-03-24
CA3052255A1 (en) 2018-08-09
SG11201906895WA (en) 2019-08-27
MA47401A (fr) 2021-05-05

Similar Documents

Publication Publication Date Title
US20250134978A1 (en) Rna cancer vaccines
JP7625568B2 (ja) 癌ワクチン
AU2018352221B2 (en) Peptides and nanoparticles for intracellular delivery of mRNA
KR102469450B1 (ko) 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
KR20190110612A (ko) 활성화 종양유전자 돌연변이 펩티드를 인코드하는 면역조절 치료 mrna 조성물
JP2024515035A (ja) ｍＲＮＡによる抗体構造及びアイソタイプの粘膜発現
KR20210038886A (ko) 개인화된 암 백신 에피토프 선택
BR112020026386A2 (pt) Composições e métodos para modulação de fenótipos inflamatórios com monócitos e macrófagos e usos de imunoterapia dos mesmos
KR20190020299A (ko) 면역 조정 폴리펩타이드를 암호화하는 mRNA의 조합물 및 이의 용도
CN111093679A (zh) 用于条件调控基因表达的方法和系统
US20220220187A1 (en) Chimeric receptor therapy
AU2022280016A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
US20250295746A1 (en) Therapeutic rna for lung cancer
NZ793715A (en) RNA cancer vaccines
NZ755780B2 (en) Rna cancer vaccines
CN117836327A (zh) 工程化的嵌合融合蛋白组合物及其使用方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601